| Item | Current | Prior | YoY % |
|---|---|---|---|
| Net Sales | ¥574.88B | ¥569.01B | +1.0% |
| Cost of Sales | ¥400.04B | ¥397.59B | +0.6% |
| Gross Profit | ¥174.85B | ¥171.41B | +2.0% |
| SG&A Expenses | ¥133.91B | ¥127.02B | +5.4% |
| Operating Income | ¥40.94B | ¥44.39B | -7.8% |
| Non-operating Income | ¥2.67B | ¥2.00B | +33.2% |
| Non-operating Expenses | ¥1.98B | ¥3.05B | -35.0% |
| Ordinary Income | ¥41.63B | ¥43.35B | -4.0% |
| Profit Before Tax | ¥39.91B | ¥44.25B | -9.8% |
| Income Tax Expense | ¥15.26B | ¥14.77B | +3.3% |
| Net Income | ¥24.65B | ¥29.48B | -16.4% |
| Net Income Attributable to Owners | ¥21.48B | ¥26.87B | -20.1% |
| Total Comprehensive Income | ¥26.55B | ¥25.98B | +2.2% |
| Depreciation & Amortization | ¥27.04B | ¥27.57B | -1.9% |
| Interest Expense | ¥303M | ¥173M | +75.1% |
| Basic EPS | ¥79.27 | ¥97.66 | -18.8% |
| Dividend Per Share | ¥50.00 | ¥50.00 | +0.0% |
| Item | Current End | Prior End | Change |
|---|---|---|---|
| Current Assets | ¥574.88B | ¥540.76B | +¥34.12B |
| Cash and Deposits | ¥69.90B | ¥78.19B | ¥-8.29B |
| Accounts Receivable | ¥207.42B | ¥189.53B | +¥17.89B |
| Inventories | ¥140.85B | ¥127.62B | +¥13.23B |
| Non-current Assets | ¥659.03B | ¥643.71B | +¥15.32B |
| Item | Current | Prior | Change |
|---|---|---|---|
| Operating Cash Flow | ¥-9.46B | ¥3.76B | ¥-13.22B |
| Investing Cash Flow | ¥-38.94B | ¥-12.19B | ¥-26.75B |
| Financing Cash Flow | ¥37.61B | ¥-17.40B | +¥55.01B |
| Free Cash Flow | ¥-48.40B | - | - |
| Item | Value |
|---|---|
| Book Value Per Share | ¥2,762.83 |
| Net Profit Margin | 3.7% |
| Gross Profit Margin | 30.4% |
| Current Ratio | 166.5% |
| Quick Ratio | 125.7% |
| Debt-to-Equity Ratio | 0.55x |
| Interest Coverage Ratio | 135.12x |
| EBITDA Margin | 11.8% |
| Effective Tax Rate | 38.2% |
| Item | YoY Change |
|---|---|
| Net Sales YoY Change | +1.0% |
| Operating Income YoY Change | -7.8% |
| Ordinary Income YoY Change | -4.0% |
| Net Income Attributable to Owners YoY Change | -20.1% |
| Total Comprehensive Income YoY Change | +2.2% |
| Item | Value |
|---|---|
| Shares Outstanding (incl. Treasury) | 282.20M shares |
| Treasury Stock | 11.10M shares |
| Average Shares Outstanding | 270.96M shares |
| Book Value Per Share | ¥2,928.28 |
| EBITDA | ¥67.98B |
| Item | Amount |
|---|---|
| Q2 Dividend | ¥50.00 |
| Year-End Dividend | ¥50.00 |
| Segment | Revenue | Operating Income |
|---|---|---|
| Food | ¥458.40B | ¥29.01B |
| Pharmaceutica002 | ¥116.99B | ¥14.32B |
| Item | Forecast |
|---|---|
| Net Sales Forecast | ¥1.18T |
| Operating Income Forecast | ¥91.00B |
| Ordinary Income Forecast | ¥87.50B |
| Net Income Attributable to Owners Forecast | ¥54.00B |
| Basic EPS Forecast | ¥197.80 |
| Dividend Per Share Forecast | ¥52.50 |
| Property, Plant & Equipment | ¥506.81B | ¥483.90B | +¥22.91B |
| Intangible Assets | ¥21.57B | ¥19.24B | +¥2.33B |
| Investment Securities | ¥69.15B | ¥78.35B | ¥-9.21B |
| Total Assets | ¥1.23T | ¥1.18T | +¥49.44B |
| Current Liabilities | ¥345.21B | ¥307.08B | +¥38.14B |
| Accounts Payable | ¥105.66B | ¥102.85B | +¥2.81B |
| Short-term Loans | ¥32.59B | ¥25.38B | +¥7.21B |
| Non-current Liabilities | ¥94.83B | ¥85.61B | +¥9.22B |
| Long-term Loans | ¥31.84B | ¥12.42B | +¥19.41B |
| Total Liabilities | ¥440.04B | ¥392.69B | +¥47.36B |
| Total Equity | ¥793.87B | ¥791.78B | +¥2.08B |
| Capital Stock | ¥30.00B | ¥30.00B | ¥0 |
| Capital Surplus | ¥38.74B | ¥38.71B | +¥35M |
| Retained Earnings | ¥653.98B | ¥649.26B | +¥4.72B |
| Treasury Stock | ¥-33.31B | ¥-33.96B | +¥649M |
| Owners' Equity | ¥749.01B | ¥748.29B | +¥726M |
| Working Capital | ¥229.67B | - | - |